WuXi Biologics (Cayman) valuation
$46.30Change from previous close: −0.94%Absolute change: −$0.44
Valuation
The P/E ratio is 35.1. The average price target of 23 analysts is $60.30.
Data as of November 17, 2026
WuXi Biologics (Cayman) compared with similar companies
WuXi Biologics (Cayman)'s P/E (trailing 12 months): 35.1, −12% against the median of a group of 8 similar companies (40.0).
| Metric | WuXi Biologics (Cayman) | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 35.1 | 40.0 | 34.2 – 60.9 | Middle |
| Forward P/E | 21.4 | 30.7 | 24.3 – 37.8 | Low |
| EV/EBITDA | 20.8 | 25.3 | 21.2 – 42.0 | Low |
| Price/book | 3.40 | 6.04 | 3.96 – 9.42 | Low |
| Price/sales | 8.14 | 10.0 | 7.09 – 17.7 | Middle |
| Gross margin | 47.5% | 73.6% | 52.7% – 76.9% | Low |
| Operating margin | 32.4% | 26.8% | 10.7% – 32.0% | High |
| Net margin | 21.2% | 11.1% | 7.2% – 26.8% | Middle |
| ROE | 11.4% | 10.4% | 5.0% – 16.3% | Middle |
| Debt/equity | 0.05 | 0.21 | 0.08 – 0.40 | Low |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $192.4B
- Enterprise value
- $188.07B
- PEG
- 0.62
- EV/revenue
- 7.96
Profitability and growth
- ROA
- 7.6%
- ROIC
- 13.9%
- Revenue growth (year over year)
- 18.4%
- Earnings growth (year over year)
- 4.3%
Financial health
- Total cash
- $13.03B
- Total debt
- $2.73B
- Current ratio
- 3.32
- Quick ratio
- 2.64
- Altman Z-Score
- 8.62
- Piotroski F-Score
- 7.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $60.30
- Median price target
- $60.57
- High price target
- $79.73
- Low price target
- $39.44
- Analysts with a price target
- 23
- Consensus
- Strong buy
- Forward EPS
- $2.18
- EPS estimate, current year
- $1.55
Shares and trading
- Beta
- 0.59
- Average volume
- 35.43M
- Shares outstanding
- 4.12B
- Float
- 3.8B
- Institutional ownership
- 37.0%
- Insider ownership
- 7.9%
